Search Results

Alora Pharmaceuticals, LLC , the parent company of Vertical Pharmaceuticals, LLC, announced today the commercial availability of Relexxii ® (methylphenidate hydrochloride extended-release tablets).

AcelRx Pharmaceuticals, Inc. today announced the divestment of its FDA-approved drug, DSUVIA® to Alora Pharmaceuticals (Alora).

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, announced the closing of its divestment of DSUVIA® to Alora Pharmaceuticals.

Alora Pharmaceuticals, LLC, is pleased to announce that its wholly owned subsidiary, Sovereign Pharmaceuticals, LLC, has acquired, through bankruptcy proceedings, substantially all of Monarch PCM, LLC’s manufacturing capabilities located in Fort Worth, TX.

Avion Pharmaceuticals, LLC, an Alora Pharmaceuticals company, announced the commercial launch of DHIVY, the first and only carbidopa/levodopa (CD/LD) fractional tablet designed to be divided. Avion gained approval for DHIVY from the FDA in November 2021.

Osmotica Pharmaceuticals plc, a specialty pharmaceutical company, announced that it has closed the previously announced sale of its legacy business, including certain of the Company’s US subsidiaries dedicated to the legacy business and its Marietta, Georgia, manufacturing facility, to Alora Pharmaceuticals, LLC, effective August 27, 2021.

Osmotica Pharmaceuticals, plc, a fully integrated biopharmaceutical company, announced that it has entered into a definitive Purchase and Sale Agreement with Alora Pharmaceuticals, LLC pursuant to which Alora will acquire Osmotica’s portfolio of legacy products and its Marietta, Georgia manufacturing facility, for up to $170 million.